(-0.01%) 5 478.00 points
(-0.02%) 38 812 points
(0.02%) 19 926 points
(0.27%) $80.55
(1.11%) $2.82
(0.11%) $2 331.50
(-0.43%) $29.27
(-0.11%) $969.80
(0.03%) $0.932
(-0.11%) $10.64
(0.08%) $0.788
(-1.86%) $86.80
Quarter results today
(bmo 2024-06-18)
Expected move: +/- 10.28%
Live Chart Being Loaded With Signals
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms...
Stats | |
---|---|
Šios dienos apimtis | 350 458 |
Vidutinė apimtis | 698 966 |
Rinkos kapitalizacija | 136.67M |
EPS | $-2.43 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.0600 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.00 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-16 | Kay Mark A | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Enyedy Mark J | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Nacht Mariana | Sell | 100 000 | Stock Option (right to buy) |
2022-11-16 | Wyzga Michael S | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Chereau Frederic | Sell | 328 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-96.11 |
Last 94 transactions |
Buy: 5 628 346 | Sell: 1 216 285 |
Tūris Koreliacija
LogicBio Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
LogicBio Therapeutics, Koreliacija - Valiuta/Žaliavos
LogicBio Therapeutics, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $287.00M |
Bruto pelnas: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2023 |
Pajamos: | $287.00M |
Bruto pelnas: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2021 |
Pajamos: | $5.41M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.240 |
FY | 2020 |
Pajamos: | $3.45M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
LogicBio Therapeutics,
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company\'s GeneRide technology is a new approach to precise gene insertion harnessing a cell\'s natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children\'s Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.